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Introduction
Despite signiﬁ  cant advances in the ﬁ  eld of gene therapy 
for cancer, two major obstacles remain that continue to 
limit the clinical potential of this approach: lack of 
tumour tropism of vectors, and stimulation of an immune 
response. Th  ese barriers preclude systemic adminis-
tration of current vectors to eﬃ   ciently target metastatic 
disease. Th  e combination of cellular therapy and gene 
delivery is an attractive option as it will potentially 
protect the vector from immune surveillance, and will 
support targeted delivery of a gene or therapeutic protein 
to the tumour site.
Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are nonhaematopoietic 
stem cells that have generated a signiﬁ  cant amount of 
interest as a result of their apparent ability to home to the 
tumour site following systemic delivery. MSCs have an 
inherent ability both to self-renew and to diﬀ  erentiate into 
multiple lineages including osteoblasts, chondrocytes and 
adipo  cytes [1]. Th  e cells are readily isolated from the 
stromal compartment of bone marrow, along with a 
number of other sources including adipose tissue, 
trabecular bone and skeletal muscle [2]. Although a 
single marker for MSCs has not been isolated, a panel of 
speciﬁ  c antigens has been identiﬁ  ed, including expression 
of CD105, CD73 and CD90 in >95% of the culture, and 
an absence of CD14, CD34, CD19, HLA-DR and CD45 
[3]. When introduced systemically to healthy animals, 
MSCs have been shown to home preferentially to the 
lung, liver and bone, and were found to a lesser extent in 
other tissues. Upon injury, however, the migratory path-
way changes to preferentially target sites of injury [4].
Although MSCs have potential uses in regenerative 
medicine and a number of diﬀ  erent disease models, the 
present review will speciﬁ  cally focus on their potential 
for targeted gene delivery in the context of cancer. Th  is  is 
an exciting area of research that has gained considerable 
momentum in recent years, with studies reporting 
engineered MSCs speciﬁ  cally targeting multiple tumour 
types followed by local secretion of therapeutic proteins 
(IFNβ [5-7], IL-2 [8,9], IL-12 [10-12], pigment epithelium-
derived factor [13], NK4 [14], TNF-related apoptosis 
inducing ligand (TRAIL) [15-18]), expression of prodrug 
activating suicide genes (herpes simplex virus-thymidine 
kinase [19-21], cytosine deaminase [22]), and delivery of 
replicating oncolytic viruses [16,19,23-25]. A major 
advan  tage of MSCs in this setting is that they are con-
sidered immunoprivileged, possibly due to low expres-
sion of Ag(HLA) MHC class 1, and no expression of 
CD40, CD80 and CD86 [4]. Th   e cells are also known to 
secrete prostaglandin, transforming growth factor beta 
and hepatocyte growth factor, which regulate the T-cell 
immune response, thereby decreasing the probability of a 
cytotoxic T-cell response to transduced cells [17].
Resident MSCs suppress both transient and continuous 
immune surveillance, which aims at facilitating the heal-
ing process [26]. Th   is immune privilege in the context of 
cancer, however, has the potential to support tumour 
progression. Djouad and colleagues reported growth of 
B16 melanoma cells in allogenic animals only in the 
presence of MSCs, suggesting that protection from the 
host immune response supported tumour establishment 
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MSCs administered in low numbers with Renca adeno-
carcinoma cells actually induced tumour rejection [28]. 
MSCs were also shown to inhibit outgrowth of colon 
carcinoma in rats, with complete inhibition seen when 
the number of MSCs were at least equal to the number of 
tumour cells. Tumour establishment using the mixed cell 
population was found to induce more inﬁ  ltration  of 
monocytes and granulocytes than the individual popu-
lations alone [29].
Th   is observation may be explained by the fact that high 
numbers of MSCs have been shown to suppress allo-
reactive T cells, with very low numbers found to stimu  late 
lymphocyte proliferation [30]. Indeed, additional evidence 
suggests that the context with which MSCs are introduced 
in vivo may inﬂ  uence their immune pheno  type [26].
Tumour tropism
Tumour-speciﬁ   c migration of MSCs is not completely 
understood, but appears to be dependent upon the 
biological properties of the tumour microenvironment, 
as well as the native tropism of selected cells. Integration 
of MSCs into the tumour stroma is thought to be 
mediated by high local concentrations of inﬂ  ammatory 
chemokines and growth factors. Th  e tumour micro-
environment is considered a site of chronic inﬂ  ammation 
[31]. Th  is environment may mediate MSC migration 
through secretion of soluble factors such as epidermal 
growth factor, vascular endothelial growth factor-A, 
ﬁ  broblast growth factor, platelet-derived growth factor, 
stromal-derived growth factor-1α (SDF-1α/CXCL12), 
IL-8, IL-6, granulocyte–macrophage colony-stimulating 
factor, granulocyte colony-stimulating factor, Ang1, 
monocyte chemoattractant protein-1 (CCL2), haemato-
poietic growth factor, transforming growth factor beta-1 
and urokinase-type plasminogen activator [32-37].
Th  e process of MSC mobilization to the tumour is 
thought to be regulated similarly to leukocyte migration 
through integrins and adhesion molecules [38]. Mole-
cules involved in leukocyte traﬃ   cking – such as tether-
ing, rolling, adhesion and transmigration from the blood-
stream to the tissue – are expressed on MSCs. Th  ese 
include integrins, selectins and chemokine recep  tors. 
Both P-selectin and vascular cell adhesion molecule-1 
have been found to inﬂ  uence the adhesion of MSCs in 
endothelium [39].
MSCs express a wide range of molecules, including 
growth factors, chemokines, adhesion molecules and 
toll-like receptors, on their surface [38-44]. MSCs are 
known to functionally express chemokine receptors 
CCR1, CCR4, CCR7, CCR9, CCR10, CXCR4, CXCR5, 
CXCR6, CX3CR1 and c-met, which has been increasingly 
linked to tumour tropism [40-43]. Th  e mechanism of 
MSC migration, however, is still not fully elucidated.
Th   e most documented chemokine receptor implicated 
in targeted homing of MSCs is CXCR4, which has 
potential in cell mobilization and homing [45]. A study by 
Wynn and colleagues reported that CXCR4 is highly 
expressed on MSCs, but mainly intracellularly (83 to 
98%) rather than on the surface [46]. Another study 
reported no detectable CXCR4 expression on MSCs [42]. 
Variable expression of CXCR4 detected in diﬀ  erent 
studies has been suggested to be related to sensitivity of 
the trypsin digestion procedure used [44], diﬀ  erences in 
culture conditions, and heterogeneity of MSC popula-
tions.  In vitro three-dimensional culture of MSCs as 
spheroids was shown to increase SDF-1α signalling, which 
restored functional expression of its receptor CXCR4 and 
homing potential that is crucial for therapeutic applica-
tions [47].
Although the tumour tropism of MSCs is generally 
accepted, it is certainly dependent on the tumour model. 
Variation in levels of MSC engraftment reported in 
diﬀ  erent studies may be explained by diﬀ  erences in MSC 
isolation, culture conditions and experimental protocols 
used. Within individual studies, however, variable levels 
of MSC engraftment have been reported in diﬀ  erent 
tumour types, most probably due to diﬀ  erences in the 
microenvironment created by the tumour in question 
[48]. Th   e proportion of MSCs engrafted was not found to 
be related to tumour size [48].
A recent study further highlighted the role that the 
degree of inﬂ  ammation in a tumour microenvironment 
plays in the level of MSC recruitment [7]. In a study of 
MSC-IFNβ-mediated therapy of pancreatic cancer, 
treatment with an anti-inﬂ  ammatory agent resulted in 
reduction of MSC engraftment in the tumour, and 
reversed the tumour inhibitory eﬀ  ects observed [7].
Enhancing tumour tropism of mesenchymal stem 
cells
Modifi  cation of the tumour microenvironment
Th  e apparent role of inﬂ   ammation in MSC tumour 
tropism has also been harnessed to increase engraftment 
through tumour irradiation, which is associated with 
release of several cytokines from exposed tissue [48,49]. 
Klopp and colleagues found that low-dose irradiation of 
the tumour microenvironment enhanced MSC tropism 
and engraftment at the tumour site [49]. Irradiation 
resulted in apoptosis and increased release of 
inﬂ  ammatory signals at the site of radiation, including 
TNFα, platelet-derived growth factor, as well as chemo-
kines CCL2 and CCR8 [49]. Th  e eﬀ   ect of tumour 
radiotherapy on localization of lentivirus-transduced 
MSCs in a variety of tumour types has also been reported 
[48]. Irradiation increased MSC localization in LoVo, 
HT-29 (colon) and MDA-231 (breast), but not UMSCC1 
(head and neck) xenografts. Th  is study also reported a 
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tumours, although it was not found to correlate with 
MSC inﬁ  ltration [48]. Inﬂ  ammation plays a critical role 
in tumour progression [50], and therefore stimulation to 
support MSC homing to tumours would not be a viable 
option. Radiotherapy is frequently a component of cancer 
therapy, however, and therefore could work in 
combination with MSC-based gene delivery to support 
improved targeting of MSCs to tumours.
Modifi  cation of the mesenchymal stem cell surface
While variations in MSC engraftment have been 
observed in diﬀ  erent tumour models, attempts are being 
made to improve tumour tropism and inﬁ  ltration 
through modiﬁ  cation of the MSC surface. Cell rolling is a 
critical step of the adhesion cascade supporting rapid 
deceleration of cells from the bloodstream, and is 
mediated by selectins expressed on the endothelium of 
the target organ. Immobilized sialyl Lewis X on MSCs 
was shown to induce cell rolling on the P-selectin surface 
under dynamic shear ﬂ  ow conditions in vitro, and may 
have potential applications in improving MSC engraft-
ment  in vivo [51]. In one study where native MSC 
tropism for the tumour of interest was not detected, 
MSCs were engineered to overexpress the epidermal 
growth factor receptor – which binds transforming 
growth factor alpha and epidermal growth factor. 
Transduced MSCs had enhanced migratory properties 
towards GL261 gliomas or B16 melanoma in vivo [52]. 
Following establishment of improved engraftment, the 
cells were further engineered to secrete IFNγ, resulting in 
increased animal survival [52].
Mesenchymal stem cell-mediated virus delivery
A signiﬁ  cant advantage of MSCs as cellular vehicles is 
their accessibility for genetic manipulation in vitro. Recent 
studies have incorporated the use of lentivirus-mediated 
transduction [13,16,48,53], retrovirus-mediated trans-
duction [10,19,20,22] or plasmid-mediated transduc  tion 
[21]; however, the majority remain adenovirus based 
[5-8,11,14,15,17,18,23-25,54,55]. MSCs have a low 
coxsackie and adenovirus receptor, high-integrin pheno-
type, which results in low transfection eﬃ   ciency using 
wildtype adenoviruses. Modiﬁ   cation of the adenovirus 
ﬁ   bre or knob domain has been used to improve 
adenovirus-mediated transgene expression. Incorpora-
tion of an arginine–glysine–aspartate motif into the 
adeno virus  ﬁ   bre or the 5/3 knob domain of human 
adenovirus serotype 3 supports coxsackie and adenovirus 
receptor-independent transfer and improves MSC trans-
duction eﬃ   ciency [14,23-25,55].
Th  is approach has evolved to include the use of 
conditionally replicating adenoviruses, which support 
delivery of an increased viral load speciﬁ   cally to the 
tumour site [23-25]. Clearly the timing is important here 
to avoid toxicity to MSCs prior to engraftment at the 
target site. Th   e cycle of MSC adenovirus replication has 
been reported to have relatively slow kinetics, which may 
allow time for MSCs to reach the target site before 
replication causes cell death [56]. Th   e delivery of 
oncolytic viruses does not rely on long-term survival and 
proliferation of cellular vehicles, as they are destroyed by 
viral replication. Capsid-modiﬁ  ed oncolytic adenoviruses 
have been coupled with the use of transcription-speciﬁ  c 
promoters to limit ectopic viral ampliﬁ   cation in non-
target cells [55]. MSCs have also been engineered to 
express the herpes simplex virus-thymidine kinase 
followed by adminis  tration of the prodrug ganciclovir for 
targeted cancer suicide gene therapy [19-21]. Based on 
similar principles, retrovirus transduction of adipose-
derived MSCs to express cytosine deaminase, followed by 
systemic adminis  tration of the prodrug 5-ﬂ  uorocysteine, 
mediated a strong anti-tumour eﬀ  ect in vivo [22].
Localized delivery of therapeutic proteins
Along with their tumour tropism, MSCs have been 
shown to integrate into and persist in the tumour stroma 
[5]. Th  is integration has supported their use as delivery 
vehicles for various biological agents, whose systemic 
administration is precluded due to their short half-life 
and toxicity at the doses required for therapy. MSCs can 
eﬃ   ciently produce biological products at tumour sites 
and so have the potential to improve pharmacokinetics of 
secreted agents [5].
In a number of tumour models, MSCs expressing IFNβ 
have been shown to result in decreased tumour burden 
and increased animal survival [5-7]. Increased systemic 
levels of IFNβ or secretion at sites distant from the 
tumour were not eﬀ   ective, indicating that regional 
secretion was required [5-7]. MSCs engineered to secrete 
IL-12 and embedded in a matrix adjacent to tumours 
were also reported to have a signiﬁ  cant therapeutic eﬀ  ect 
[10]. Similar to ﬁ  ndings in the case of IFNβ, regional 
secretion was required, with no reduction in growth 
observed when the implant was placed in the opposite 
ﬂ  ank to the tumour [10].
MSCs expressing the hepatocyte growth factor antago-
nist NK4 in vivo were also found to prolong animal sur-
vival by inhibiting tumour-associated angiogenesis, 
lympho  angiogenesis and induction of cancer cell apop-
tosis [14]. Local secretion of pigment epithelium-derived 
factor in a model of hepatocellular carcinoma through 
lentivirus transduction of MSCs similarly resulted in 
lower tumour volume, reduced lung metastases and 
improved survival through inhibition of tumour angio-
genesis [13].
Further, MSCs secreting IL-2 [8,9] or IL-12 [10,11] 
were shown to elicit an immunological reaction, and to 
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tissue. Th  e observed anticancer eﬀ  ect was shown to be 
immune mediated and absent in immunodeﬁ  cient 
animals [10]. Delivery of MSC-IL-12 did not cause 
systemic toxicity, and resulted in increased serum and 
tumour levels of IL-12. In contrast, administration of 
Ad-IL-12 only increased serum IL-12 levels and induced 
systemic toxicity [11]. Th  erefore it appears that MSC-
mediated local delivery of a therapeutic agent may be 
better tolerated by the host without inducing an 
unacceptable immune response [11].
TRAIL induces caspase-mediated apoptosis in tumour 
cells that overexpress the receptor. Like most healthy 
tissues, MSCs are resistant to TRAIL-induced apoptosis 
due to their very low levels of active receptors [17]. As a 
result of this, MSCs secreting TRAIL have been used in 
models of lung cancer, breast cancer, cervical cancer and 
brain cancer in vivo, resulting in signiﬁ  cant anti-tumour 
eﬀ  ects [15-18,53]. In one study using a lentiviral vector, 
TRAIL expression was placed under the control of a tet 
promoter, supporting conditional activation using doxy-
cycline [16]. In an animal model of lung metastases of 
breast cancer, this controlled, local delivery of TRAIL 
completely cleared metastatic disease in a selection of 
animals [16]. Interestingly, when MSC-TRAIL cells were 
co-injected with tumour cells for subcutaneous tumour 
formation, only doxycycline-mediated activation on the 
day of tumour cell inoculation (day 0) caused a signiﬁ  cant 
decrease in tumour weight. Activation following tumour 
establishment (day 25) did not result in a change in 
tumour burden [16].
Potential role in tumourigenesis
Although beyond the scope of the current review, the 
potential role of MSCs in tumour initiation or promotion 
is a signiﬁ  cant concern that must be addressed fully to 
allow MSC-mediated therapy for cancer to realize its full 
potential. Th   is role remains a topic of continued debate. 
Expansion of MSCs in vitro will be required for thera-
peutic application and so their stability in culture is 
paramount. Spontaneous transformation of human 
MSCs has been reported following long-term passage in 
vitro [57,58], while Bernardo and colleagues found no 
evidence of human MSC transformation [59]. Indeed the 
majority of studies have shown that human MSCs are 
stable, while murine MSCs are more prone to genetic 
transformation during in vitro culture, and may be 
capable of forming sarcomas in vivo [59-63]. Although 
transformation of human MSCs appears unlikely, and 
very rare, these studies certainly emphasize the impor-
tance of stringent monitoring of MSCs, including karyo-
typing, before application in the clinical setting.
MSCs have also been implicated as tumour supportive 
when co-injected in the presence of a variety of tumour 
cell types, including breast [64-67], ovarian [68], mela-
noma [27], glioma [69,70] and colon [71,72] tumour cells. 
Th   e majority of these studies, however, used an equal or 
even excess number of MSCs over tumour cells. Th  e  data 
generated provide important information on interactions 
between MSCs and tumour cells, although the models 
are unlikely to reﬂ  ect the in vivo situation. MSCs were 
shown to integrate into the tumour stroma and were 
demonstrated to exert their eﬀ  ects at least partly through 
secretion of paracrine factors including CCL5, IL-6 and 
SDF-1α [64,65,68]. Th   ere is also evidence that MSCs may 
serve as precursors for carcinoma-associated ﬁ  broblasts 
and/or pericytes, playing a potentially important role in 
tumour angiogenesis through diﬀ   erentiation and the 
release of proangiogenic factors [67-69,71-76]. Addition-
ally, as previously mentioned, the immunosuppressive 
qualities of MSCs may support tumour development and 
progression through protection of cancer cells from 
immune surveillance [27].
Conversely, co-injection of MSCs has also been shown 
to result in tumour suppression in a model of colon 
cancer [29], hepatoma [77] and melanoma [78].
In terms of MSC-mediated gene delivery, under  stand-
ing the role of MSCs following engraftment at the site of 
a pre-established tumour is required. Th  e majority of 
studies outlined here, using MSCs engineered to deliver 
therapeutic agents, have resulted in signiﬁ  cant  anti-
tumour eﬀ  ects  in vivo. Unmodiﬁ   ed MSCs were also 
shown to result in tumour suppression in some cases 
[7,8,79], with the majority showing no eﬀ  ect on tumour 
progression following engraftment at the site of an 
established tumour [13,18,23,53,55,69,75]. Repeat intra-
venous administration of MSCs over 3 weeks, however, 
was shown to stimulate increased tumour growth in a 
model of pancreatic cancer [21]. Similar to the level of 
MSC engraftment in tumours, it seems that the eﬀ  ect of 
MSCs following engraftment will be tumour speciﬁ  c – 
probably dependent on a range of factors including the 
method of MSC isolation and culture, the experimental 
model, the number of cells engrafted in the tumour, and 
the milieu of growth factors and inﬂ  ammatory cytokines 
present within the tumour microenvironment.
Conclusion
Th  e studies outlined highlight very promising potential 
for MSC-mediated delivery of therapeutic agents directly 
to tumour tissue, with remarkable progress made in the 
past decade. Clearly MSCs have a number of advantages 
as cellular vehicles – they are relatively easy to isolate and 
expand, speciﬁ  cally target tumours and their metastases 
following systemic delivery, can be transduced eﬃ   ciently 
with a range of vectors, have immuno  suppressive 
properties, have the ability to express therapeutic 
proteins in secretory form and can support ampliﬁ  cation 
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tumour promotion, however, must be addressed. Further 
understanding the biology of MSCs, and the speciﬁ  c 
combination of factors controlling their tumour-speciﬁ  c 
migration and persistence, will support translation to the 
clinical setting.
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